| Initiation of antiretroviral therapy in early asymptomatic HIV infection Insight Start Study Group New England Journal of Medicine 373 (9), 795-807, 2015 | 3308 | 2015 |
| HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment KP Singh, M Crane, J Audsley, A Avihingsanon, J Sasadeusz, SR Lewin Aids 31 (15), 2035-2052, 2017 | 277 | 2017 |
| Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single … A Pozniak, JR Arribas, J Gathe, SK Gupta, FA Post, M Bloch, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 71 (5), 530-537, 2016 | 213 | 2016 |
| A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand GV Matthews, A Avihingsanon, SR Lewin, J Amin, R Rerknimitr, ... Hepatology 48 (4), 1062-1069, 2008 | 171 | 2008 |
| Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults S Walmsley, A Avihingsanon, J Slim, DJ Ward, K Ruxrungtham, J Brunetta, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 50 (4), 367-374, 2009 | 154 | 2009 |
| Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial RT Davey, E Fernández-Cruz, N Markowitz, S Pett, AG Babiker, ... The Lancet Respiratory Medicine 7 (11), 951-963, 2019 | 131 | 2019 |
| Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin GS Nagy, S Tsiodras, LD Martin, A Avihingsanon, A Gavrila, WC Hsu, ... Clinical infectious diseases 36 (6), 795-802, 2003 | 128 | 2003 |
| Treatment strategy for rifampin-susceptible tuberculosis NI Paton, C Cousins, C Suresh, E Burhan, KL Chew, VB Dalay, Q Lu, ... New England Journal of Medicine 388 (10), 873-887, 2023 | 123 | 2023 |
| Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)–coinfected individuals after the initiation of HBV-active antiretroviral therapy M Crane, B Oliver, G Matthews, A Avihingsanon, S Ubolyam, V Markovska, ... The Journal of infectious diseases 199 (7), 974-981, 2009 | 112 | 2009 |
| Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study K Squires, C Kityo, S Hodder, M Johnson, E Voronin, D Hagins, ... The lancet HIV 3 (9), e410-e420, 2016 | 109 | 2016 |
| COVID-19 and HIV infection co-pandemics and their impact: a review of the literature S Gatechompol, A Avihingsanon, O Putcharoen, K Ruxrungtham, ... AIDS research and therapy 18 (1), 28, 2021 | 108 | 2021 |
| Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand W Manosuthi, S Ongwandee, S Bhakeecheep, M Leechawengwongs, ... AIDS research and therapy 12, 1-9, 2015 | 106 | 2015 |
| Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised … JH Beigel, Y Bao, J Beeler, W Manosuthi, A Slandzicki, SM Dar, J Panuto, ... The Lancet Infectious Diseases 17 (12), 1255-1265, 2017 | 99 | 2017 |
| Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study RL Puls, P Srasuebkul, K Petoumenos, C Boesecke, C Duncombe, ... Clinical infectious diseases 51 (7), 855-864, 2010 | 85 | 2010 |
| Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis SM Gygli, PM Keller, M Ballif, N Blöchliger, R Hömke, M Reinhard, ... Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 02175-18, 2019 | 83 | 2019 |
| Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus GV Matthews, EC Seaberg, A Avihingsanon, S Bowden, GJ Dore, ... Clinical Infectious Diseases 56 (9), e87-e94, 2013 | 83 | 2013 |
| CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV WM Han, T Apornpong, SJ Kerr, A Hiransuthikul, S Gatechompol, T Do, ... AIDS research and therapy 15, 1-9, 2018 | 79 | 2018 |
| Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality N Durier, J Ananworanich, T Apornpong, S Ubolyam, SJ Kerr, ... Clinical infectious diseases 57 (1), 147-155, 2013 | 75 | 2013 |
| Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial A Carr, B Grund, J Neuhaus, A Schwartz, JI Bernardino, D White, ... HIV medicine 16, 137-146, 2015 | 72 | 2015 |
| A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial SS Solomon, S Wagner-Cardoso, L Smeaton, LA Sowah, C Wimbish, ... The Lancet Gastroenterology & Hepatology 7 (4), 307-317, 2022 | 71 | 2022 |
